Although RCC is sensitive to immunotherapy, interferon-α with or without interleukin-2 (IL-2) yields unsatisfactory response (10%–20%) and long-term progression-free survival (PFS) rates of 4%–15% [51–53].Although the introduction of novel immunotherapeutic agents, such as anti-PDL-1 antibodies (nivolumab and ipilimumab) provided some improvement in overall survival rates of RCC patients, none of the current drugs have a curative potential in RCC [54]. The gene discussed is IL2; the disease is renal cell carcinoma.